Multiple studies defining macrophage-cancer cell fusion hybrids as cancer cells expressing the monocyte/macrophage lineage marker hemoglobin-haptoglobin complex scavenger receptor, CD163, have demonstrated a significant decrease in overall survival and distant recurrence-free survival in patients with greater numbers of CD163-positive tumor cells in their primary tumor (34, 67). Here, CD163 is linked to neoplasm.